
  
    
      
        Background_NNP
        Premature_NNP ovarian_NN failure_NN is_VBZ a_DT condition_NN characterized_VBN
        by_IN cessation_NN of_IN normal_JJ ovarian_NN function_NN before_IN the_DT age_NN of_IN
        40_CD ._. In_IN most_JJS cases_VBZ a_DT precise_JJ mechanism_NN for_IN the_DT ovarian_NN
        failure_NN is_VBZ not_RB identified_VBN ;_: however_RB ,_, there_EX is_VBZ evidence_NN
        suggesting_VBG a_DT genetic_JJ mechanism_NN in_IN at_IN least_JJS some_DT cases_NNS ._. [_NN 1_CD
        2_CD 3_CD 4_CD ]_NN
        Normal_NNP ovarian_NN function_NN in_IN reproductive-aged_JJ women_NNS is_VBZ
        dependent_JJ upon_IN the_DT presence_NN of_IN a_DT store_NN of_IN functional_JJ
        primordial_JJ follicles_NNS ._. This_DT store_NN develops_VBZ from_IN primordial_JJ
        germ_NN cells_NNS ,_, a_DT small_JJ population_NN of_IN cells_NNS that_WDT differentiate_VB
        from_IN other_JJ cell_NN lineages_NNS in_IN very_RB early_JJ embryonic_JJ life_NN ._. [_NN 5_CD
        ]_NN Premature_NNP depletion_NN of_IN primordial_JJ follicles_NNS is_VBZ a_DT known_VBN
        mechanism_NN of_IN premature_JJ ovarian_NN failure_NN ._. [_NN 6_CD 7_CD ]_NN
        Studies_NNS in_IN mice_NNS have_VBP demonstrated_VBN that_IN c-kit_JJ ,_, a_DT
        transmembrane_NN tyrosine_NN kinase_NN receptor_NN ,_, plays_VBZ a_DT critical_JJ
        role_NN in_IN hematopoeisis_NNS ,_, melanogenesis_NNS ,_, and_CC gametogenesis_NNS ._.
        The_DT c-kit_JJ receptor_NN kinase_NN and_CC its_PRP$ ligand_NN KL_NNP (_( kit_NN ligand_NN ,_,
        stem_VB cell_NN factor_NN )_) are_VBP encoded_JJ at_IN the_DT white_JJ spotting_VBG (_( W_NNP )_) and_CC
        steel_NN (_( Sl_NNP )_) loci_NN of_IN the_DT mouse_NN ,_, respectively_RB ._. Various_JJ
        mutations_NNS at_IN the_DT W_NNP and_CC the_DT Sl_NNP loci_NN have_VBP been_VBN shown_VBN to_TO cause_VB
        anemia_NN ,_, pigmentation_NN defects_NNS ,_, and_CC sterility_NN ._. [_NN 8_CD ]_NN Point_NNP
        mutations_NNS in_IN the_DT Kit_NNP receptor_NN tyrosine_NN kinase_NN in_IN mice_NNS can_MD
        selectively_RB impair_VB fertility_NN without_IN inducing_VBG detectable_JJ
        abnormalities_NNS in_IN hematopoesis_NNS or_CC pigmentation_NN ._. [_NN 9_CD ]_NN
        Studies_NNPS employing_VBG cultured_JJ mouse_NN primordial_JJ germ_NN cells_NNS have_VBP
        demonstrated_VBN that_IN the_DT Steel_NNP /_NN Kit_NNP interaction_NN is_VBZ required_VBN for_IN
        germ_NN cell_NN survival_NN ._. [_NN 10_CD 11_CD 12_CD ]_NN
        These_DT observations_NNS in_IN mice_NNS suggest_VBP that_IN mutations_NNS in_IN the_DT
        human_JJ 
        KIT_NNP gene_NN (_( MIM_NNP 164920_CD )_) might_MD be_VB a_DT
        cause_NN of_IN premature_JJ ovarian_NN failure_NN in_IN women_NNS ._. The_DT human_JJ 
        KIT_NNP gene_NN is_VBZ located_VBN on_IN chromosome_NN 4_CD
        at_IN map_NN locus_JJ 4_CD q_NN 12_CD ._. Mutations_NNP in_IN the_DT human_JJ 
        KIT_NNP gene_NN have_VBP been_VBN identified_VBN as_IN a_DT
        cause_NN of_IN Piebaldism_NNP ,_, a_DT rare_JJ autosomal_NN dominant_JJ disorder_NN of_IN
        melanogenesis_NNS characterized_VBN by_IN patchy_NN absence_NN of_IN
        pigmentation_NN of_IN the_DT skin_NN and_CC overlying_VBG hair_NN ._. [_NN 13_CD 14_CD ]_NN Here_RB
        we_PRP test_VBP the_DT hypothesis_NNS that_IN specific_JJ human_JJ 
        KIT_NNP mutations_NNS might_MD be_VB a_DT cause_NN of_IN
        spontaneous_JJ premature_JJ ovarian_NN failure_NN even_RB in_IN the_DT absence_NN
        of_IN detectable_JJ disorders_NNS of_IN pigmentation_NN or_CC
        hematopoesis_NNS ._.
      
      
        Methods_NNP
        
          Subjects_NNP
          Our_PRP$ institutional_JJ review_NN board_NN approved_VBN the_DT study_NN and_CC
          all_DT participants_NNS signed_VBD an_DT informed_VBN consent_NN and_CC the_DT
          procedures_NNS of_IN the_DT study_NN were_VBD in_IN compliance_NN with_IN the_DT
          Helsinki_NNP Declaration_NNP ._. The_DT study_NN population_NN comprised_VBN 42_CD
          women_NNS with_IN premature_JJ ovarian_NN failure_NN and_CC 10_CD normal_JJ
          healthy_JJ control_NN women_NNS who_WP had_VBD regular_JJ menses_NNS and_CC proven_VBN
          fertility_NN ._. Referring_VBG physicians_NNS made_VBD the_DT diagnosis_NN of_IN
          premature_JJ ovarian_NN failure_NN based_VBN on_IN the_DT following_JJ
          criteria_NNS :_: development_NN of_IN at_IN least_JJS 4_CD months_NNS of_IN amenorrhea_NN
          before_IN age_NN 40_CD associated_VBN with_IN two_CD serum_NN FSH_NNP levels_NNS above_IN
          40_CD IU_NNP /_NN L_NNP (_( drawn_VBN at_IN least_JJS 1_CD month_NN apart_RB )_) ._. Women_NNS with_IN
          premature_JJ ovarian_NN failure_NN as_IN a_DT result_NN of_IN surgery_NN ,_,
          radiation_NN ,_, chemotherapy_NN ,_, or_CC known_VBN karyotype_NN abnormalities_NNS
          were_VBD not_RB included_VBN in_IN the_DT study_NN ._. Patients_NNS who_WP had_VBD not_RB
          previously_RB had_VBD a_DT karyotype_NN analysis_NN were_VBD included_VBN pending_VBG
          our_PRP$ analaysis_NNS ._. There_EX were_VBD 34_CD Caucasian_NNP ,_, 6_CD African_NNP
          American_NNP and_CC two_CD Hispanic_JJ women_NNS ._. The_DT median_JJ age_NN at_IN the_DT
          onset_NN of_IN menstrual_JJ irregularity_NN was_VBD 25_CD years_NNS (_( range_NN 14_CD to_TO
          39_CD ,_, 25_CD thpercentile_NN 18_CD ._. 5_LS ,_, 75_CD thpercentile_NN 34_CD )_) ._. Five_CD women_NNS
          had_VBD a_DT family_NN history_NN of_IN premature_JJ ovarian_NN failure_NN (_( two_CD
          patients_NNS had_VBD sisters_NNS with_IN premature_JJ ovarian_NN failure_NN ,_, one_CD
          patient_NN 's_POS mother_NN had_VBD premature_JJ ovarian_NN failure_NN ,_, one_CD had_VBD a_DT
          paternal_NN aunt_NN with_IN premature_JJ ovarian_NN failure_NN ,_, and_CC one_CD
          patient_NN had_VBD a_DT paternal_NN aunt_NN ,_, a_DT grandmother_NN ,_, and_CC a_DT
          great-grandmother_JJ who_WP were_VBD thought_VBN to_TO have_VB the_DT
          condition_NN )_) ._. All_DT patients_NNS underwent_VBD a_DT history_NN and_CC physical_JJ
          examination_NN and_CC laboratory_NN screening_NN to_TO confirm_VB the_DT
          diagnosis_NN of_IN premature_JJ ovarian_NN failure_NN ._.
        
        
          Cytogenetics_NNP
          Karyotypes_NNP were_VBD obtained_VBN on_IN all_DT patients_NNS ._. Peripheral_NNP
          blood_NN specimens_NNS were_VBD cultured_JJ for_IN 72_CD -_: 96_CD hours_NNS using_VBG
          standard_JJ methods_NNS and_CC methotrexate-thymidine_JJ
          synchronization_NN ._. [_NN 15_CD ]_NN Harvesting_NNP and_CC GTW-banding_NNP were_VBD
          also_RB performed_VBN according_VBG to_TO standard_JJ cytogenetic_JJ
          protocols_NNS ._. [_NN 16_CD ]_NN Fifty_NNP metaphases_NNS were_VBD examined_VBN for_IN each_DT
          patient_NN and_CC scored_VBD for_IN numerical_JJ or_CC structural_JJ chromosome_NN
          abnormalities_NNS ._. Band_NNP resolution_NN was_VBD at_IN the_DT 600_CD band_NN stage_NN
          or_CC higher_JJR ._.
          Fluorescence_NNP in_IN situ_NN hybridization_NN (_( FISH_NNP )_) was_VBD
          performed_VBN on_IN metaphases_NNS from_IN cultured_JJ lymphocytes_NNS of_IN two_CD
          patients_NNS with_IN abnormal_JJ G-_NNP band_NN findings_NNS ._. Chromosome_NNP and_CC
          probe_NN denaturation_NN ,_, hybridization_NN ,_, detection_NN ,_, and_CC
          counterstaining_VBG were_VBD all_DT done_VBN according_VBG to_TO standard_JJ
          protocols_NNS as_IN recommended_VBN by_IN the_DT manufacturer_NN ._.
        
        
          DNA_NN extraction_NN and_CC polymerase_NN chain_NN reaction_NN
          (_( PCR_NNP )_)
          Genomic_NNP DNA_NNP was_VBD extracted_VBN from_IN peripheral_JJ blood_NN using_VBG
          standard_JJ procedures_NNS ._. Specific_JJ primers_NNS for_IN PCR_NNP
          amplification_NN of_IN the_DT exons_NNS were_VBD designed_VBN based_VBN on_IN the_DT
          human_JJ KIT_NNP genomic_JJ sequence_NN (_( Genebank_NNP accession_NN number_NN
          AC_NNP 006553_CD ,_, Human_NNP chromosome_NN 4_LS )_) (_( Table_NNP 1_LS )_) ._. In_IN exon_NN 21_CD the_DT
          reverse_JJ primer_NN is_VBZ located_VBN in_IN the_DT 3_CD '_POS noncoding_VBG region_NN ,_, in_IN
          all_DT other_JJ cases_VBZ the_DT primers_NNS are_VBP located_VBN at_IN introns_NNS
          flanking_VBG each_DT exon_NN ._. The_DT PCR_NNP amplification_NN was_VBD carried_VBN out_IN
          in_IN a_DT total_JJ volume_NN of_IN 25_CD μl_NN reaction_NN mixture_NN containing_VBG
          1_CD ._. 5_CD mmol_NN /_NN l_NN of_IN MgCL_NNP 
          2_CD ,_, 0_CD ._. 2_CD mmol_NN /_NN l_NN of_IN each_DT dNTP_NN ,_, 50_CD ng_NN of_IN
          genomic_JJ DNA_NNP ,_, 0_CD ._. 5_CD μm_NN of_IN each_DT primer_NN ,_, and_CC 1_CD ._. 25_CD IU_NNP of_IN 
          Taq_NNP DNA_NNP polymerase_NN per_IN
          manufacturer_NN 's_POS instructions_NNS (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) ._.
          The_DT PCR_NNP began_VBD with_IN an_DT initial_JJ denaturing_VBG at_IN 95_CD °_NN C_NNP for_IN 5_CD
          minutes_NNS ._. Thereafter_RB the_DT cycling_NN profile_NN consisted_VBD of_IN 35_CD
          cycles_NNS of_IN denaturing_VBG at_IN 95_CD °_NN C_NNP for_IN 30_CD seconds_NNS ,_, annealing_VBG of_IN
          the_DT primer_NN pair_NN at_IN the_DT appropriate_JJ temperature_NN for_IN 30_CD
          seconds_NNS (_( Table_NNP 1_LS )_) ,_, and_CC then_RB extension_NN at_IN 72_CD °_NN C_NNP for_IN 60_CD
          seconds_NNS ._. This_DT was_VBD followed_VBN by_IN a_DT final_JJ stabilization_NN step_NN
          of_IN 10_CD minutes_NNS at_IN 72_CD °_NN C_NNP ._. After_IN PCR_NNP ,_, 5_CD μl_NN of_IN the_DT amplified_VBN
          product_NN was_VBD examined_VBN by_IN 1_CD ._. 5_CD %_NN agarose_NN gel_NN
          electrophoresis_NNS ._.
        
        
          Single-stranded_NNP conformational_NN polymorphism_NN (_( SSCP_NNP )_)
          analysis_NN
          Analysis_NNP of_IN DNA_NNP polymorphism_NN was_VBD conducted_VBN using_VBG a_DT
          method_NN of_IN "_'' Cold_NNP SSCP_NNP "_'' as_IN described_VBN previously_RB ._. [_NN 17_CD ]_NN
          Briefly_NNP ,_, the_DT PCR_NNP products_NNS (_( 4_CD μl_NN )_) were_VBD mixed_VBN with_IN SSCP_NNP
          sample_NN buffer_NN (_( 6_CD μl_NN ,_, formamide_NN with_IN 0_CD ._. 05_CD %_NN bromophenol_NN
          blue_NN and_CC xylene_NN cyanol_NN )_) ._. After_IN denaturing_VBG at_IN 95_CD °_NN C_NNP for_IN 5_CD
          minutes_NNS ,_, the_DT DNA_NNP samples_NNS were_VBD placed_VBN on_IN ice_NN immediately_RB
          and_CC loaded_VBN onto_IN precast_NN 20_CD %_NN TBE_NNP acrylamide_NN gels_NNS (_( Tris_NNP
          Base_NNP ,_, Boric_NNP Acid_NNP ,_, EDTA_NNP ,_, 4_CD %_NN glycerol_NN ,_, and_CC 20_CD %_NN acrylamide_NN ,_,
          Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) ._. Gel_NNP elecrophoresis_NNS was_VBD run_VBN in_IN
          1_CD X_NNP TBE_NNP buffer_NN at_IN 200_CD V_NNP with_IN the_DT circulator_NN set_VBN at_IN 4_CD °_NN C_NNP
          (_( using_VBG a_DT Penquin_NNP Water-cooled_NNP Dual-_NNP Gel_NNP Electrophoresis_NNP
          system_NN attached_VBN to_TO a_DT thermostatically_RB controlled_VBN
          refrigerated_JJ circulator_NN ,_, Amersham_NNP &_CC Pharmacia_NNP ,_,
          Uppsala_NNP ,_, Sweden_NNP )_) ._. Gels_NNP were_VBD stained_JJ with_IN ethidium_NN bromide_NN
          (_( 1_CD μg_NN /_NN ml_NN )_) for_IN 20_CD minutes_NNS at_IN room_NN temperature_NN ._. DNA_NN bands_NNS
          were_VBD visualized_JJ and_CC photographed_VBN under_IN UV_NNP light_JJ (_( 340_CD
          nm_NN )_) ._.
        
        
          Direct_NNP DNA_NNP sequencing_VBG
          PCR_NNP products_NNS were_VBD either_CC purified_JJ using_VBG ExoSAP-IT_NNP (_( USB_NNP
          Co_NNP ,_, Cleveland_NNP ,_, OH_NNP )_) or_CC subcloned_JJ into_IN a_DT TA_NNP cloning_VBG vector_NN
          (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) per_IN the_DT manufacturer_NN 's_POS
          instructions_NNS ._. DNA_NNP sequencing_VBG was_VBD conducted_VBN by_IN PCR_NNP (_( 26_CD
          cycles_NNS of_IN 96_CD °_NN C_NNP ,_, 10_CD seconds_NNS ;_: 50_CD °_NN C_NNP 5_CD seconds_NNS ;_: 60_CD °_NN C_NNP 4_CD
          minutes_NNS )_) using_VBG a_DT dRhodamine_NN terminator_NN cycle_NN sequencing_VBG
          kit_NN (_( PE_NNP Applied_NNP Biosystems_NNP ,_, Foster_NNP ,_, CA_NNP )_) and_CC 10_CD μl_NN of_IN
          purified_JJ PCR_NNP product_NN or_CC 1_CD μg_NN of_IN purified_JJ plasmid_NN DNA_NNP ._. The_DT
          sequencing_VBG samples_NNS were_VBD separated_VBN by_IN 5_CD %_NN Long_NNP Ranger_NNP gel_NN
          electrophoresis_NNS on_IN the_DT ABI_NNP Automatic_NNP 310_CD Sequencer_NNP
          (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP ,_, CA_NNP )_)
        
      
      
        Results_NNS
        
          Clinical_NNP
          None_NN of_IN the_DT 42_CD women_NNS were_VBD found_VBN to_TO have_VB clinical_JJ
          findings_NNS to_TO suggest_VB Turner_NNP syndrome_NN ._. None_NN of_IN the_DT patients_NNS
          had_VBD clinical_JJ or_CC laboratory_NN findings_NNS to_TO suggest_VB a_DT stem_NN
          cell_NN deficiency_NN in_IN melanogenesis_NNS or_CC hematopoiesis_NNS ._. Two_CD
          women_NNS were_VBD found_VBN to_TO have_VB partial_JJ monosomy_NN of_IN the_DT X_NNP
          chromosome_NN that_WDT was_VBD felt_VBN to_TO be_VB related_VBN to_TO the_DT
          presentation_NN of_IN spontaneous_JJ premature_JJ ovarian_NN failure_NN ._.
          For_IN this_DT reason_NN they_PRP were_VBD excluded_VBN from_IN further_JJ analysis_NN ._.
          These_DT findings_NNS highlight_NN the_DT usefulness_NN of_IN careful_JJ
          cytogenetic_JJ screening_NN of_IN women_NNS with_IN spontaneous_JJ premature_JJ
          ovarian_NN failure_NN ._. The_DT remaining_VBG 40_CD women_NNS had_VBD a_DT normal_JJ
          46_CD ,_, XX_NNP karyotype_NN analysis_NN ._.
          One_CD woman_NN of_IN normal_JJ stature_NN had_VBD a_DT karyotype_NN analysis_NN
          showing_VBG :_: 46_CD ,_, X_NNP ,_, ?_. rec_NN (_( X_NNP )_) dup_NN (_( Xp_NNP )_) inv_NN (_( X_NNP )_) (_( p_NN 11_CD ._. 4_LS q_NN 24_CD )_) ._. ish_NN
          rec_NN (_( X_NNP )_) dup_NN (_( Xp_NNP )_) inv_NN (_( X_NNP )_) (_( p_NN 11_CD ._. 4_LS q_NN 24_CD )_) (_( KAL_NNP +_NN +_NN )_) ._. In_IN all_DT cells_NNS
          examined_VBD there_EX was_VBD one_CD normal_JJ X_NNP chromosome_NN and_CC one_CD X_NNP
          chromosome_NN that_WDT had_VBD most_JJS of_IN Xp_NNP (_( Xp_NNP 11_CD ._. 4_LS →_NN Xpter_NNP )_) replacing_VBG a_DT
          portion_NN of_IN Xq_NNP (_( Xq_NNP 24_CD →_NN Xqter_NNP )_) ._. This_DT rearrangement_NN was_VBD
          confirmed_VBN with_IN a_DT FISH_NNP study_NN ._. A_DT probe_NN to_TO the_DT Kallman_NNP
          syndrome_NN region_NN (_( Oncor_NNP Inc_NNP ._. ,_, Gaithersburg_NNP ,_, MD_NNP )_) at_IN Xp_NNP 22_CD ._. 3_LS
          was_VBD hybridized_JJ to_TO patient_NN 's_POS metaphases_NNS and_CC showed_VBD signal_NN
          on_IN both_DT ends_NNS of_IN the_DT abnormal_JJ X_NNP chromosome_NN (_( as_RB well_RB as_IN the_DT
          normal_JJ X_NNP chromosome_NN )_) confirming_VBG the_DT G-_NNP band_NN impression_NN
          that_IN both_DT ends_NNS of_IN this_DT chromosome_NN was_VBD comprised_VBN of_IN Xp_NNP ._. In_IN
          summary_NN ,_, the_DT patient_NN had_VBD partial_JJ trisomy_NN Xp_NNP and_CC partial_JJ
          monosomy_NN Xq_NNP as_IN demostrated_JJ by_IN G-_NNP banding_VBG and_CC FISH_NNP ._.
          A_DT second_JJ woman_NN of_IN normal_JJ stature_NN had_VBD a_DT karyotype_NN
          analysis_NN showing_VBG :_: 46_CD ,_, X_NNP ,_, der_NN (_( X_NNP )_) t_NN (_( X_NNP ;_: 13_CD )_) (_( q_NN 22_CD ._. 3_LS ;_: q_NN 14_CD ._. 1_LS )_) ._.
          All_DT cells_NNS examined_VBD in_IN this_DT patient_NN had_VBD extra_JJ material_NN on_IN
          Xq_NNP which_WDT was_VBD 13_CD q_NN in_IN origin_NN ._. FISH_NNP was_VBD performed_VBN using_VBG
          whole_JJ chromosome_NN probes_NNS to_TO the_DT X_NNP and_CC 13_CD (_( Oncor_NNP ,_,
          Gaithersburg_NNP ,_, MD_NNP )_) ._. The_DT X_NNP probe_NN showed_VBD signal_NN covering_VBG the_DT
          entire_JJ normal_JJ X_NNP as_RB well_RB as_IN Xp_NNP and_CC the_DT proximal_NN half_NN of_IN Xq_NNP
          on_IN the_DT derivative_JJ chromosome_NN ._. Whole_JJ chromosome_NN probe_NN 13_CD
          showed_VBD signal_NN on_IN the_DT normal_JJ 13_CD as_RB well_RB as_IN on_IN the_DT
          derivative_JJ X_NNP chromosome_NN ._. These_DT results_NNS are_VBP consistant_NN
          with_IN partial_JJ monosomy_NN Xq_NNP from_IN q_NN 22_CD →_NN q_NN terminus_JJ and_CC partial_JJ
          trisomy_NN 13_CD from_IN q_NN 14_CD ._. 1_LS →_NN q_NN terminus_JJ ._. Given_VBN the_DT lack_NN of_IN
          symptoms_NNS /_NN characteristics_NNS associated_VBN with_IN trisomy_NN 13_CD
          (_( multiple_JJ congenital_NN anomolies_NNS with_IN severe_JJ cognitive_JJ
          delays_NNS )_) we_PRP hypothesize_NN that_IN the_DT derivative_JJ X_NNP chromosome_NN
          is_VBZ the_DT inactivated_JJ X_NNP ,_, thus_RB sparing_VBG the_DT patient_NN the_DT
          expected_VBN phenotype_NN ._.
        
        
          Screening_NNP of_IN the_DT KITgene_NNP
          All_DT the_DT exons_NNS of_IN the_DT gene_NN (_( Figure_NN 1_CD A_DT )_) were_VBD
          successfully_RB amplified_VBN by_IN PCR_NNP in_IN all_DT 10_CD controls_NNS and_CC all_DT
          40_CD patients_NNS with_IN 46_CD ,_, XX_NNP spontaneous_JJ premature_JJ ovarian_NN
          failure_NN ._. Except_IN for_IN product_NN 21_CD ,_, which_WDT carried_VBD only_RB the_DT
          coding_VBG region_NN ,_, each_DT PCR_NNP product_NN contained_VBD one_CD complete_JJ
          exon_NN ._. All_DT PCR_NNP products_NNS were_VBD of_IN the_DT expected_VBN size_NN ._. As_IN
          shown_VBN in_IN Figure_NN 1_CD B_NNP ,_, the_DT size_NN of_IN the_DT 21_CD PCR_NNP products_NNS
          ranged_VBD from_IN 198_CD to_TO 438_CD bp_NN and_CC all_DT appeared_VBD as_IN a_DT single_JJ
          clear_JJ band_NN ._.
          The_DT PCR_NNP products_NNS were_VBD screened_VBD for_IN mutations_NNS by_IN SSCP_NNP
          analysis_NN ._. We_PRP found_VBD mobility_NN shifts_NNS in_IN the_DT PCR_NNP products_NNS
          from_IN two_CD of_IN the_DT patients_NNS and_CC none_NN of_IN the_DT controls_NNS ._. As_IN
          shown_VBN in_IN Figure_NN 2_CD ,_, patient_NN 4_CD had_VBD a_DT mobility_NN shift_NN in_IN the_DT
          products_NNS from_IN two_CD exons_NNS ,_, 10_CD and_CC 16_CD ;_: patient_NN 5_CD had_VBD a_DT
          mobility_NN shift_NN in_IN the_DT product_NN from_IN exon_NN 17_CD ._. In_IN patient_NN 4_CD
          both_DT the_DT polymorphisms_NNS were_VBD determined_VBN by_IN sequencing_VBG to_TO
          be_VB within_IN intron_NN regions_NNS ,_, and_CC would_MD thus_RB not_RB change_VB the_DT
          sequence_NN of_IN the_DT c-_NN KIT_NNP protein_NN ._. In_IN the_DT polymorphism_NN 71_CD
          nucleotides_NNS upstream_RB of_IN exon_NN 10_CD ,_, substitution_NN at_IN
          nucleotide_NN 71_CD replaced_VBD the_DT normal_JJ T_NN with_IN an_DT A_DT
          [_NN IVS_NNP 9_CD -_: 71_CD T_NN >_NN A_DT ]_NN ._. In_IN the_DT polymorphism_NN downstream_JJ of_IN exon_NN
          16_CD there_EX was_VBD a_DT deletion_NN of_IN 5_CD T_NN nucleotides_NNS from_IN within_IN a_DT
          normal_JJ series_NN of_IN 22_CD consecutive_JJ T_NN nucleotides_NNS [_NN IVS_NNP 16_CD
          +_NN 66_CD __NN +_NN 70_CD delTTTTT_NN ]_NN (_( Figure_NN 3_LS )_) ._. In_IN patient_NN 5_CD sequencing_VBG
          uncovered_VBD a_DT mutation_NN at_IN codon_NN 798_CD ;_: however_RB ,_, the_DT mutation_NN
          C_NNP 798_CD T_NN was_VBD silent_JJ with_IN no_DT change_NN in_IN amino_JJ acid_NN sequence_NN
          (_( Isoleucine_NNP )_) ._.
        
        
          Restriction_NNP Fragment_NNP Length_NNP Polymorphism_NNP
          Analysis_NNP
          The_DT C_NNP 798_CD T_NN substitution_NN in_IN exon_NN 17_CD of_IN patient_NN 5_CD
          generates_VBZ a_DT new_JJ restriction_NN site_NN for_IN 
          Ssp_NNP I_PRP (_( AAT_NNP ATT_NNP )_) ._. To_TO determine_VB if_IN
          this_DT mutation_NN was_VBD homozygous_JJ or_CC heterozygous_JJ we_PRP analysed_JJ
          restriction_NN fragment_NN length_NN polymorphism_NN (_( RFLP_NNP )_) on_IN PCR_NNP
          products_NNS ._. As_IN shown_VBN in_IN Figure_NN 4_CD ,_, the_DT mutant_JJ PCR_NNP product_NN
          (_( 390_CD bp_NN )_) for_IN exon_NN 17_CD was_VBD digested_VBN with_IN SspI_NNP to_TO yield_VB two_CD
          shorter_JJR DNA_NNP fragments_NNS only_RB (_( 207_CD and_CC 183_CD bp_NN )_) ._. These_DT data_NNS
          suggest_VBP that_IN this_DT mutation_NN is_VBZ homozygous_JJ ._. We_PRP did_VBD not_RB
          perform_VB RFLP_NNP analysis_NN on_IN the_DT mutant_JJ PCR_NNP products_NNS from_IN
          exons_NNS 10_CD and_CC 16_CD because_IN no_DT new_JJ restriction_NN sites_NNS were_VBD
          generated_VBN by_IN the_DT mutations_NNS ._. Other_JJ methodologies_NNS such_JJ as_IN
          forced_VBN RFLP_NNP and_CC sequencing_VBG of_IN multiple_JJ cloned_VBN products_NNS
          could_MD be_VB applied_VBN to_TO determine_VB if_IN these_DT mutations_NNS are_VBP
          homozygous_JJ or_CC heterozygous_JJ ._.
        
      
      
        Discussion_NNP
        Primordial_NNP germs_NNS cells_NNS originate_VB from_IN a_DT small_JJ number_NN of_IN
        progenitor_NN cells_NNS that_WDT arise_VBP in_IN very_RB early_JJ development_NN ._.
        Thereafter_RB ,_, complex_JJ factors_NNS that_WDT are_VBP not_RB well_RB understood_VBN
        direct_JJ their_PRP$ proliferation_NN ,_, survival_NN ,_, migration_NN to_TO the_DT
        genital_JJ ridge_NN ,_, differentiation_NN into_IN oocytes_NNS ,_, and_CC the_DT
        subsequent_JJ expenditure_NN of_IN oocytes_NNS via_IN ovulation_NN or_CC
        apoptotic_JJ death_NN ._. [_NN 5_CD 7_CD ]_NN [_NN 18_CD ]_NN Mutations_NNP or_CC deletions_NNS in_IN
        any_DT of_IN the_DT genes_NNS involved_VBN in_IN this_DT complex_JJ process_NN could_MD
        theoretically_RB be_VB a_DT cause_NN of_IN premature_JJ ovarian_NN failure_NN on_IN
        the_DT basis_NN of_IN germ_NN cell_NN deficiency_NN ,_, either_CC due_JJ to_TO a_DT
        deficient_NN initial_JJ endowment_NN of_IN primordial_JJ follicles_NNS or_CC an_DT
        accelerated_VBN expenditure_NN of_IN this_DT endowment_NN ._.
        Evidence_NN that_IN genetic_JJ factors_NNS play_VBP a_DT role_NN in_IN some_DT cases_NNS
        of_IN premature_JJ ovarian_NN failure_NN has_VBZ been_VBN around_IN for_IN a_DT long_JJ
        time_NN [_NN 19_CD 20_CD ]_NN ._. However_RB ,_, the_DT small_JJ pedigrees_NNS necessarily_RB
        associated_VBN with_IN this_DT condition_NN make_NN it_PRP extremely_RB difficult_JJ
        to_TO conduct_VB genetic_JJ linkage_NN analysis_NN that_WDT can_MD be_VB used_VBN to_TO
        identify_VB candidate_NN genes_NNS ._. [_NN 4_CD ]_NN One_CD approach_NN to_TO this_DT
        dilemma_NN has_VBZ been_VBN to_TO evaluate_VB candidate_NN genes_NNS based_VBN on_IN
        existing_VBG knowledge_NN of_IN ovarian_NN physiology_NN ,_, as_IN has_VBZ been_VBN
        reported_VBN in_IN the_DT case_NN of_IN inhibin_NN ._. [_NN 21_CD ]_NN Other_JJ candidate_NN
        genes_NNS are_VBP those_DT that_IN when_WRB mutated_VBN are_VBP known_VBN to_TO cause_VB germ_NN
        cell_NN deficiency_NN in_IN other_JJ species_NNS ,_, for_IN example_NN the_DT
        diaphanous_JJ gene_NN of_IN drosophila_NN ._. [_NN 22_CD ]_NN Numerous_JJ growth_NN
        factors_NNS have_VBP been_VBN associated_VBN with_IN primordial_JJ germ_NN cell_NN
        behavior_NN during_IN migration_NN in_IN mice_NNS using_VBG 
        in_IN vitro_NN studies_NNS ,_, but_CC in_IN most_JJS cases_NNS
        it_PRP is_VBZ unknown_JJ whether_IN these_DT factors_NNS function_VBP 
        in_IN vivo_NN ._. [_NN 5_CD ]_NN One_CD exception_NN is_VBZ the_DT
        Steel_NNP /_NN Kit_NNP interaction_NN ._. 
        Steel_NNP and_CC 
        W_NNP are_VBP genetic_JJ loci_NN identified_VBN in_IN
        strains_NNS of_IN mice_NNS that_WDT exhibit_NN sterility_NN on_IN the_DT basis_NN of_IN germ_NN
        cell_NN deficiency_NN ._. The_DT products_NNS of_IN these_DT two_CD loci_NN are_VBP now_RB
        known_VBN to_TO be_VB the_DT tyrosine_NN kinase_NN receptor_NN Kit_NNP (_( 
        W_NNP )_) and_CC its_PRP$ ligand_NN Steel_NNP factor_NN (_( 
        Steel_NNP )_) ._. It_PRP was_VBD on_IN this_DT basis_NN that_IN we_PRP
        set_VBD out_IN to_TO examine_VB patients_NNS with_IN premature_JJ ovarian_NN failure_NN
        for_IN mutations_NNS in_IN 
        KIT_NNP ._.
        The_DT SSCP_NNP technique_NN has_VBZ been_VBN used_VBN successfully_RB for_IN
        mutation_NN searching_VBG in_IN other_JJ genes_NNS ._. [_NN 23_CD 24_CD 25_CD 26_CD ]_NN Using_VBG
        the_DT PCR-SSCP_NNP technique_NN we_PRP were_VBD able_JJ to_TO detect_VB only_RB one_CD
        polymorphism_NN in_IN the_DT entire_JJ coding_VBG regions_NNS of_IN the_DT 
        KIT_NNP gene_NN ,_, and_CC this_DT polymorphism_NN did_VBD
        not_RB change_VB the_DT amino_JJ acid_NN sequence_NN at_IN codon_NN 798_CD ._. Therefore_RB ,_,
        these_DT results_NNS suggest_VBP that_IN mutations_NNS in_IN the_DT coding_VBG regions_NNS
        of_IN the_DT 
        KIT_NNP gene_NN are_VBP unlikely_JJ to_TO be_VB a_DT common_JJ
        cause_NN of_IN premature_JJ ovarian_NN failure_NN ._. The_DT upper_JJ 95_CD %_NN
        confidence_NN limit_NN of_IN the_DT proportion_NN 0_CD /_NN 40_CD is_VBZ 7_CD ._. 2_CD %_NN (_( no_DT
        mutations_NNS found_VBD in_IN 40_CD women_NNS with_IN 46_CD ,_, XX_NNP spontaneous_JJ
        premature_JJ ovarian_NN failure_NN )_) ._. The_DT DNA_NNP polymorphisms_NNS that_IN we_PRP
        identified_VBD within_IN intron_NN regions_NNS upstream_RB of_IN exon_NN 10_CD and_CC
        downstream_JJ of_IN exon_NN 16_CD would_MD not_RB change_VB the_DT amino_JJ acid_NN
        sequence_NN of_IN the_DT c-_NN KIT_NNP protein_NN ._. However_RB ,_, we_PRP cannot_NN exclude_VBP
        the_DT possibility_NN that_IN these_DT changes_NNS in_IN nucleotides_NNS that_WDT are_VBP
        close_RB to_TO exons_NNS might_MD alter_VB c-_NN KIT_NNP transcription_NN ,_, or_CC that_IN
        mutations_NNS in_IN the_DT regulatory_JJ regions_NNS of_IN the_DT 
        KIT_NNP gene_NN might_MD be_VB a_DT cause_NN of_IN
        spontaneous_JJ premature_JJ ovarian_NN failure_NN ._. Furthermore_RB ,_, it_PRP
        should_MD be_VB noted_VBN that_IN SSCP_NNP methodology_NN does_VBZ not_RB detect_VB all_DT
        mutations_NNS of_IN PCR_NNP products_NNS ._. Although_IN in_IN this_DT report_NN using_VBG
        this_DT technique_NN we_PRP were_VBD able_JJ to_TO detect_VB a_DT single_JJ nucleotide_NN
        mutation_NN in_IN a_DT PCR_NNP product_NN of_IN 390_CD bp_NN ,_, most_JJS laboratories_NNS
        would_MD suggest_VB that_IN SSCP_NNP detects_NNS approximately_RB 70_CD to_TO 80_CD %_NN of_IN
        mutations_NNS ._. Screening_NNP a_DT larger_JJR group_NN of_IN patients_NNS with_IN a_DT more_RBR
        sensitive_JJ technique_NN such_JJ as_IN denaturing_VBG high-performance_JJ
        liquid_JJ chromatography_NN might_MD detect_VB more_JJR mutations_NNS ._.
      
      
        Conclusions_NNP
        We_PRP were_VBD unable_JJ to_TO detect_VB any_DT significant_JJ mutations_NNS in_IN
        the_DT entire_JJ coding_VBG region_NN of_IN the_DT 
        KIT_NNP gene_NN in_IN 40_CD patients_NNS with_IN 46_CD ,_, XX_NNP
        spontaneous_JJ premature_JJ ovarian_NN failure_NN ._. Therefore_RB ,_, mutations_NNS
        in_IN the_DT coding_VBG regions_NNS of_IN the_DT 
        KIT_NNP gene_NN do_VBP not_RB appear_VB to_TO be_VB a_DT common_JJ
        cause_NN of_IN 46_CD ,_, XX_NNP spontaneous_JJ premature_JJ ovarian_NN failure_NN in_IN
        North_JJ American_JJ women_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        K_NNP ._. S_NNP ._. ,_, Z-B_NNP ._. T_NN ,_, and_CC K_NNP ._. V_NNP ._. participated_VBD in_IN the_DT design_NN of_IN the_DT
        study_NN and_CC carried_VBD out_RP the_DT molecular_JJ genetic_JJ laboratory_NN
        studies_NNS ._. K_NNP ._. S_NNP ._. and_CC Z-B_NNP ._. T_NN ._. drafted_VBD the_DT manuscript_NN ._. V_NNP ._. H_NNP ._. V_NNP ._.
        recruited_VBD the_DT patients_NNS and_CC helped_VBD characterized_VBN them_PRP
        clinically_RB ._. L_NNP ._. M_NNP ._. N_NNP ._. conceived_VBD the_DT study_NN ,_, participated_VBD in_IN its_PRP$
        design_NN ,_, coordination_NN ,_, analysis_NN and_CC manuscript_NN preparation_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
